Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Recurrence × Etoposide × Clear all

Phase

Status

Completed 21 Terminated 8 Unknown 5 Active not recruiting 4 Not yet recruiting 3 Recruiting 2 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 9 Lymphoma 7 Small Cell Lung Carcinoma 5 Lymphoma, Non-Hodgkin 4 Lung Neoplasms 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Lymphoma, Large-Cell, Immunoblastic 3 Lymphoma, Follicular 3 Hodgkin Disease 3 Carcinoma, Non-Small-Cell Lung 3 Burkitt Lymphoma 3 Waldenstrom Macroglobulinemia 2 Sarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Lymphoma, Mantle-Cell 2 Lymphoma, Large-Cell, Anaplastic 2 Lymphoma, B-Cell, Marginal Zone 2 Lymphoma, AIDS-Related 2 Leukemia, Myeloid, Acute 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Dendritic Cell Sarcoma, Interdigitating 2 Unspecified Adult Solid Tumor, Protocol Specific 1 Testicular Neoplasms 1 Testicular Germ Cell Tumor 1 Sezary Syndrome 1 Rhabdoid Tumor 1 Retinoblastoma 1 Recurrence 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Neuroectodermal Tumors, Primitive 1

Interventions

Dexamethasone 8 venetoclax 4 Rituximab 4 selinexor 3 pembrolizumab 3 ibrutinib 3 Lenalidomide 3 Gemcitabine 3 Drug Therapy 3 Cytarabine 3 Bendamustine Hydrochloride 3 gilteritinib 2 fludarabine phosphate 2 carfilzomib 2 Tablets 2 Surveys and Questionnaires 2 Oxaliplatin 2 Cetuximab 2 Calcium Dobesilate 2 Busulfan 2 Bortezomib 2 Azacitidine 2 vistusertib 1 urelumab 1 tucotuzumab celmoleukin 1 trametinib 1 tocilizumab 1 tisagenlecleucel 1 thymoglobulin 1 temsirolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00776802 2013-06-25

GCS-100LE

La Jolla Pharmaceutical Company

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡